FDA Approves Pivmecillinam for Treatment of Female Adults With Urinary Tract Infections
April 24th 2024Pivmecillinam (Pivya; UTILITY therapeutics Ltd) tablets were approved for female adults with uncomplicated urinary tract infection caused by Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.
Read More
The Fludarabine Shortage and Its Ripple Effects: Navigating the Crisis
The significant surge in oncology drug shortages in 2023 particularly affected essential chemotherapeutic drugs.
Read More
Integration of these agents requires supportive care considerations for cytokine release syndrome, neurotoxicity, infection, and antigen-specific toxicities to ensure optimal care of patients with multiple myeloma receiving T-cell–engaging therapies.
Read More